Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $40.00 Price Target at Guggenheim

Posted by George Bondi on Jun 25th, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) had its price target raised by Guggenheim from $30.00 to $40.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would suggest a potential upside of 125.52% from the company’s previous close.

A number of other research firms also recently weighed in on AMLX. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Amylyx Pharmaceuticals in a research note on Monday, June 8th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Mizuho lifted their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

View Our Latest Analysis on Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Stock Up 4.3%

AMLX stock traded up $0.74 during midday trading on Thursday, reaching $17.74. The stock had a trading volume of 287,086 shares, compared to its average volume of 1,253,192. The business has a fifty day simple moving average of $15.11 and a two-hundred day simple moving average of $14.34. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -11.76 and a beta of -0.16. Amylyx Pharmaceuticals has a twelve month low of $5.97 and a twelve month high of $18.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, equities analysts predict that Amylyx Pharmaceuticals will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after buying an additional 3,102,395 shares in the last quarter. Perceptive Advisors LLC grew its stake in Amylyx Pharmaceuticals by 0.4% in the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after acquiring an additional 28,017 shares during the period. TCG Crossover Management LLC grew its stake in Amylyx Pharmaceuticals by 5.0% in the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after acquiring an additional 300,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Amylyx Pharmaceuticals by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock worth $70,123,000 after acquiring an additional 531,162 shares in the last quarter. Finally, Commodore Capital LP increased its holdings in shares of Amylyx Pharmaceuticals by 38.6% in the fourth quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock worth $68,252,000 after acquiring an additional 1,574,522 shares in the last quarter. 95.84% of the stock is owned by institutional investors.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.